MRM-HEALTH
MRM Health—a clinical-stage biopharmaceutical company focused on developing next-generation live microbiome consortia therapeutics—today announced that its Type-2 Diabetes Program, developed in collaboration with IFF (NYSE: IFF) has achieved preclinical development targets. With the achievement of this new milestone, both companies will now advance this research which focuses on developing innovative therapies for metabolic diseases to the clinical development stage.
IFF joined forces with microbiome specialist MRM Health in 2020, aiming to tackle a range of metabolic diseases. In this research, the proprietary MRM Health CORAL® technology platform and some selected IFF strains will be combined to develop novel therapeutics based on live bacterial strain combinations.
“We are very pleased to see the progress that MRM Health and IFF have made within our partnership programs in metabolic health,” said Oliver Hasselwander, technical fellow, IFF. “By reaching this preclinical milestone in the diabetes program, MRM Health has further demonstrated that their technology platform is unique in identifying next generation microbiome solutions, and we look forward to developing these together with MRM Health.”
The gut microbiome has a recognized role in non-alcoholic fatty liver disease (NAFLD) and associated diseases such as Type-2 diabetes and obesity. The two companies will continue the NAFLD program to further build on promising lead consortia. IFF and MRM Health’s collaboration on NAFLD will enable both parties to build upon the preclinical results, showing that a nine-strain bacterial consortium delays NAFLD progression and liver fibrosis. Part of this work was recently published in Biomedicines.
"This second milestone achievement is an important step in demonstrating our team's expertise and the capacity of our unique CORAL® platform to deliver differentiated microbiome therapeutics across different diseases,” said Sam Possemiers, CEO and co-founder of MRM Health. “We are delighted to be working with IFF to rapidly drive the program through this preclinical phase, and we are confident that our technologies have the potential to deliver future life-changing oral therapeutics for patients."
MRM Health’s CORAL® platform utilizes a bioinformatics-guided in-human discovery engine, combined with a breakthrough in optimization and manufacturing of consortia as single drug substance. The proprietary consortia optimization technology allows for the development of next-generation consortia therapeutics with faster onset-of-action and increased potency and robustness. The breakthrough scalable, robust, and standardized cGMP-compliant consortia manufacturing technology allows to manufacture complete therapeutic consortia as a single drug substance in a single manufacturing process which strongly surpasses existing approaches in speed, reduced complexity, increased robustness and lower cost.
About MRM Health
MRM Health NV, Ghent, Belgium, is a biopharmaceutical company focused on the development of next-generation optimized consortium therapeutics based on the human microbiome. The company has built a diversified pipeline with its proprietary CORAL® platform to design, optimize, and manufacture bacterial consortia as single drug substance. Its most advanced program MH002 is an optimized consortium of 6 rationally-selected and well-characterized commensal strains. MH002 is currently being studied in two Phase 2 studies in patients with mild-to-moderate Ulcerative Colitis and acute Pouchitis, respectively. Additional pipeline development includes a preclinical program in Parkinson’s disease, preclinical programs in Type 2 Diabetes and in NAFLD (both partnered with IFF, previously DuPont), and a discovery program in autoimmune disease, including spondyloarthritis.
Welcome to IFF
At IFF (NYSE: IFF), an industry leader in food, beverage, health, biosciences and scent, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn.
** END**
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221213005040/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CSG Xponent Sweeps Up Top-Tier Analyst, Industry Recognition for Customer Journey Management, Analytics10.12.2025 14:30:00 CET | Press release
Independent evaluations from QKS Group, FinTech Futures and CMP Research validate CSG Xponent as a driver of real-time journey orchestration and analytics CSG® (NASDAQ: CSGS) today announced that its flagship customer engagement platform, CSG Xponent, has earned multiple honors for journey management, customer analytics and personalization. This third-party recognition underscores the strength of CSG Xponent as a full-service engagement platform – one that seamlessly combines in-depth journey analytics with real-time orchestration. In the past month alone, CSG Xponent has been named: A Leader in QKS Group’s SPARK Matrix™: Customer Journey Management, 2025. Winner for “Best Personalisation and User Experience Solution” in the FinTech Futures 2025 Banking Tech Awards. A Core Performing provider in CMP Research’s Prism for Customer Analytics. “CSG Xponent moves beyond broad segmentation to pinpoint each customer’s journey state, whether stalled, at-risk or ready to convert, and then quant
AI Power Surge and Energy Transition Push Global Project Finance into a New Era10.12.2025 14:30:00 CET | Press release
70% of finance professionals expect infrastructure to drive the strongest growth, followed by renewables (48%) and TMT (43%).53% now view private equity as a primary source of equity funding, signaling a major shift in capital dynamics.80% cite KYC requirements as the top execution challenge amid rising deal complexity. Global project finance is entering a transformative era, driven by soaring demand for energy capacity, accelerated digitalization and large-scale infrastructure upgrades, reshaping investment priorities worldwide. These insights come from new research commissioned by CSC, based on responses from 200 project finance professionals, revealing a market shifting toward more complex, capital-intensive projects and a greater reliance on private capital. CSC’s latest report, Project Finance at an Inflection Point: Adapting to New Realities1, reveals a sector that is rapidly expanding in both scale and complexity driven by capital increasingly targeting long-term, strategically
Kingswood Capital Management Enters Into a Definitive Agreement to Acquire Safran Passenger Innovations10.12.2025 14:00:00 CET | Press release
SPI is a leading global provider of in-flight entertainment and connectivity solutions for airlines and airplane manufacturers worldwide Kingswood Capital Management, LP (together with its affiliates, “Kingswood”) announced today that it has entered into a definitive agreement to acquire Safran Passenger Innovations (“SPI” or the “Company”) from Safran, an international high-tech company operating in the aviation, defense, and space markets. SPI is a leading global provider of in-flight entertainment and connectivity solutions for airlines and airplane manufacturers worldwide. Matt Smith will continue to serve as SPI’s CEO, and the entire SPI leadership team will remain in place. The transaction is expected to close early next year, subject to customary legal and regulatory requirements. Headquartered in Brea, California, SPI created and designed an award-winning in-flight entertainment and connectivity platform known as RAVE, recognized for its intuitive design, reliability, and innov
Armis Partners with KODE Labs and IntelliBuild to Streamline Security Operations Across the Building Management Lifecycle10.12.2025 14:00:00 CET | Press release
Integration secures smart building systems, empowering organizations to enhance their cyber resilience and make more informed decisions Armis, the cyber exposure management & security company, today announced a strategic partnership with KODE Labs and IntelliBuild to help organizations unify cybersecurity, operational intelligence and governance for building lifecycle management. The joint offering combines Armis’ continuous asset intelligence with KODE Labs’ performance trends and analytics, which are then operationalized by IntelliBuild’s governance and reporting. By translating accurate, verified intelligence into accountable action, organizations can streamline the operations of building management systems – from thermostats, lighting and badge readers to elevator controllers and security cameras – and proactively strengthen their cyber defenses. “To achieve real security in the new age of connected environments, you must have comprehensive, real-time protection across the entire a
FiRa Unveils New Membership Tier to Fuel Industry Growth10.12.2025 14:00:00 CET | Press release
New pricing model invites more companies to join FiRa’s collaborative ecosystem. FiRa® Consortium is expanding its membership structure with a new Associate tier that opens the door to broader industry involvement. With new revenue-based pricing, organizations of all sizes can now more easily help shape the future of precise, secure wireless experiences. By reducing cost-related barriers and expanding access to FiRa resources, this new tier opens the door for innovators, developers, and emerging players to contribute to the next generation of wireless capabilities. The updated structure gives companies a more flexible and accessible path to Associate membership: $7,500 USD for companies with annual revenue below $50 million USD $30,000 USD for companies with annual revenue above $50 million USD The refreshed Associate tier maintains all existing benefits, including participation in FiRa Working Groups, access to specifications, engagement in FiRa Plugfests, product certification opport
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom